, /PRNewswire/ -- Alida Biosciences (AlidaBio), an innovator in epigenomic research tools, proudly announces the successful completion of a Series A funding round. This funding, led by Genoa Ventures with participation from FusionX Ventures and Vertical Venture Partners, is complemented by two ongoing SBIR grants totaling from The National Human Genome Research Institute (NHGRI). Additionally, AlidaBio unveils the Early Access launch of two products: the EpiPlexTM RNA Library Prep Kit and the EpiScoutTM Analysis Suite.
These products provide a comprehensive solution for multiplexed epitranscriptomic analysis of input-limited clinical research RNA samples, offering unprecedented sensitivity and accuracy. is designed to revolutionize epitranscriptomic research by enabling unprecedented multiplexed detection of RNA modifications. This kit integrates a streamlined assay workflow with an intuitive bioinformatics platform, facilitating high-sensitivity analysis of RNA modifications.
The epitranscriptome, consisting of a diverse array of naturally occurring RNA modifications, plays a crucial role in regulating RNA biology, including RNA-protein interactions, splicing, three-dimensional RNA structure, transcript stability, intracellular trafficking, and translation. Traditional methods, relying on antibody-based and chemical approaches, are limited to detecting a single type of modification per assay and require high input amounts of RNA. The EpiPlex kit overcomes these limitations b.
